This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Albright, A. L. Search for Related Content PubMed PubMed Citation Articles by Albright, A. L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cerebral Palsy Social Bookmarking                         What's this?

Topical Review: Baclofen in the Treatment of Cerebral Palsy

Departments of Neurosurgery, Children's Hospital of Pittsburgh and University of Pittsburgh School of Medicine, Pittsburgh, PA

Baclofen, a -aminobutyric acid agonist, acts at the spinal cord level to impede the release of excitatory neurotransmitters that cause spasticity. Oral baclofen improves cerebral spasticity mildly, but its activity is limited because of its poor lipid solubility. Cerebrospinal fluid baclofen levels after intrathecal administration are many times higher than those achieved after oral administration. Continuous intrathecal baclofen infusion has been used to treat cerebral spasticity in two patient groups: in older ambulatory children with inadequate underlying leg strength, and in patients with severe spasticity in both the upper and lower extremities. Responsiveness to intrathecal baclofen is confirmed by test injections before insertion of a programmable subcutaneous pump. Continuous intrathecal baclofen infusion dosages vary from 27 to 800 µg/day. Continuous intrathecal baclofen infusion reduces spasticity in the upper and lower extremities, and improves upper extremity function and activities of daily living but has no effect on athetosis in the dosages used to treat spasticity. Complications related to the intrathecal catheter occur in approximately 20% of patients, and infection requiring pump removal occurs in approximately 5%. Preliminary studies indicate that continuous intrathecal baclofen infusion alleviates some forms of generalized dystonia associated with cerebral palsy. (J Child Neurol 1996;11:77-83).

Journal of Child Neurology, Vol. 11, No. 2, 77-83 (1996)
DOI: 10.1177/088307389601100202


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. A. Brumback The Silver Jubilee: Journal of Child Neurology Turns 25 J Child Neurol, January 1, 2010; 25(1): 4 - 31. [PDF]

				P. Watson Modulation of involuntary movements in cerebral palsy with acupuncture Acupunct Med, June 1, 2009; 27(2): 76 - 78. [Abstract] [Full Text] [PDF]

				M. Kofler, E. Quirbach, R. Schauer, M. Singer, and L. Saltuari Limitations of Intrathecal Baclofen for Spastic Hemiparesis Following Stroke Neurorehabil Neural Repair, January 1, 2009; 23(1): 26 - 31. [Abstract] [PDF]

				A. I. Dai, M. Wasay, and S. Awan Botulinum Toxin Type A with Oral Baclofen Versus Oral Tizanidine: A Nonrandomized Pilot Comparison in Patients with Cerebral Palsy and Spastic Equinus Foot Deformity J Child Neurol, December 1, 2008; 23(12): 1464 - 1466. [Abstract] [PDF]

				L. Lubsch, R. Habersang, M. Haase, and S. Luedtke Oral Baclofen and Clonidine for Treatment of Spasticity in Children J Child Neurol, December 1, 2006; 21(12): 1090 - 1092. [Abstract] [PDF]

				J H Patrick, A P Roberts, and G F Cole Therapeutic choices in the locomotor management of the child with cerebral palsy{---}more luck than judgement? Arch. Dis. Child., October 1, 2001; 85(4): 275 - 279. [Full Text] [PDF]

				H. S. Singer, J. Wendlandt, M. Krieger, and J. Giuliano Baclofen treatment in Tourette syndrome: A double-blind, placebo-controlled, crossover trial Neurology, March 13, 2001; 56(5): 599 - 604. [Abstract] [Full Text] [PDF]

				E. M. Goldstein Spasticity Management: An Overview J Child Neurol, January 1, 2001; 16(1): 16 - 23. [Abstract] [PDF]

				A. L. Albright and B. L. Shultz Plasma Baclofen Levels in Children Receiving Continuous Intrathecal Baclofen Infusion J Child Neurol, June 1, 1999; 14(6): 408 - 409. [Abstract] [PDF]

				A. L. Albright Intrathecal Baclofen in Cerebral Palsy Movement Disorders J Child Neurol, November 1, 1996; 11(1_suppl): S29 - S35. [Abstract] [PDF]

				J. B. Bodensteiner The Management of Cerebral Palsy: Subjectivity and a Conundrum J Child Neurol, March 1, 1996; 11(2): 75 - 76. [PDF]